lnvesting in Oncology Forum, 2024

Welcome to the lnvesting in Oncology Forum 2024 - focusing on what difference Swedish commercial drug development can make in creating the cancer therapies of tomorrow. The develop­ ment of new, improved cancer treatments is always of great interest. In Sweden, a number of listed companies are active in the cancer fleld and have drug projects in the clinical phase.

lnvesting in Oncology Forum strives to offer a better understanding of some of the most interesting drug projects and how they may develop in the future. We will look doser into the participating companies' most important investments. Through panel discussions, we will also get a picture of how the clinics and the doctors, who work on a daily basis to give cancer patients the best possible treatments, view the need for new therapies, new combination treatments and new approaches.

What to focus on if you invest in the area? Our panel of institutional investors will give an insight in their reasoning when investing in the fleld, dubbed "What's hot and what's not". We will also be given an international outlook by Principal Consultant Alex Bour, from the international data and media house Citeline.

Participating companies presenting their most valuable and potentially value-creating projects are:

Active Biotech I Biolnvent I Biovica I Cantargia I Medivir I Mendus I Oncopeptides I Oryzon

The forum will be moderated by Charlotte Stjerngren, Cord Communications.

lnvesting in Oncology Forum 2024 is hosted by Cord Communications.

The program is aimed at those who are interested in investments in the pharmaceutical sector, who are shareholders in such companies or who work clinically in the cancer field.

För att deltaga på plats vänligen maila info@cordcom.se